Add BrightSurf on Google Email

Study pinpoints key mechanism of brain aging

A new study by Stanford researchers reveals that declining proteostasis in the brain leads to increased protein aggregation, which is linked to neurodegenerative diseases. The findings were made using the turquoise killifish model, and shed light on the fundamental molecular principles of aging.

SourceStanford University·JournalScience·DateJul 31, 2025

Clinical potential of undercarboxylated osteocalcin in metabolic and neurodegenerative diseases: From biomarker to therapeutic target

Research examines undercarboxylated osteocalcin's impact on diabetes, osteoporosis, Alzheimer's disease, and other conditions like NAFLD and depression. Glu-OCN's influence on glucose homeostasis, lipid metabolism, and cholesterol metabolism is discussed.

SourceShanghai Jiao Tong University Journal Center·JournalLabMed Discovery·TypeObservational study·DateJul 30, 2025

New study validates insulin nasal spray to deliver Alzheimer’s drug directly to the brain

A groundbreaking brain imaging study confirms intranasal insulin safely reaches key memory regions in older adults with Alzheimer's. The research reveals differences in uptake among individuals with early cognitive decline, paving the way for personalized treatment approaches.

SourceAtrium Health Wake Forest Baptist·JournalAlzheimer s & Dementia Translational Research & Clinical Interventions·DateJul 23, 2025

NTU Singapore and Oxford scientists reveal how cells repair toxic DNA damage linked to cancer and premature ageing

Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.

SourceNanyang Technological University·JournalNucleic Acids Research·TypeExperimental study·DateJul 21, 2025

How the brain controls its blood volume

Researchers discovered a two-step mechanism where inhibitory neurons release nitric oxide to rapidly dilate blood vessels, followed by slower, localized vasodilation via astrocyte activation. This breakthrough sheds light on how neural signals are translated into blood volume changes in brain imaging.

SourceInstitute for Basic Science·JournalNature Communications·TypeExperimental study·DateJul 21, 2025

AI can accelerate search for more effective Alzheimer’s medicines by streamlining clinical trials

Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.

SourceUniversity of Cambridge·JournalNature Communications·DateJul 17, 2025

What long COVID-19, ME/CFS, and neuroscience have in common and to gain from one another

Long-haul COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome share similar pathophysiologies, including oxidative stress, autoantibodies, and impaired mitochondrial energy conversion. These conditions also exhibit neurodegenerative outcomes, such as fatigue, sleep disturbances, and increased risk of dementia.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalNeuroprotection·TypeLiterature review·DateJul 16, 2025

Weekly injection could be life changing for Parkinson’s patients

Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.

SourceUniversity of South Australia·JournalDrug Delivery and Translational Research·TypeExperimental study·DateJul 13, 2025

New study maps four key pathways to Alzheimer’s disease

Researchers identified four distinct pathways leading to Alzheimer's disease, revealing how conditions progress step-by-step toward the condition. The study validated findings in a nationally diverse population, suggesting that understanding these pathways could fundamentally change how clinicians approach early detection and prevention.

SourceUniversity of California - Los Angeles Health Sciences·JournalEBioMedicine·TypeData/statistical analysis·DateJul 7, 2025

UCLA researchers uncover key mechanism of brain repair in vascular dementia, revealing promising therapeutic target

Researchers at UCLA Health have made a groundbreaking discovery about the mechanisms underlying vascular dementia. They found that targeting inflammation in brain blood vessels can promote brain repair and functional recovery in mice. This breakthrough highlights a potential new treatment approach for this understudied form of dementia.

SourceUniversity of California - Los Angeles Health Sciences·JournalCell·TypeExperimental study·DateJun 30, 2025

USC researchers define brain scan marker to better classify Alzheimer’s disease-related changes

A new brain imaging benchmark may improve how researchers classify biologically meaningful changes associated with Alzheimer’s disease. Researchers found a tau cut-point that distinguished individuals with cognitive impairment from those aging normally, but its effectiveness was limited in non-Hispanic Black participants.

SourceKeck School of Medicine of USC·JournalImaging Neuroscience·TypeImaging analysis·DateJun 26, 2025

Targeting newly-identified brain protein brings hope of new treatment for Parkinson's disease

Researchers at the University of Sydney have identified a new brain protein involved in Parkinson's disease and found that targeting it with a drug treatment improved motor function in experimental models. The study suggests that this approach could slow or stop the progression of Parkinson's disease in humans.

SourceUniversity of Sydney·JournalActa Neuropathologica Communications·TypeExperimental study·DateJun 25, 2025

New study uncovers brain damage progression in Alzheimer's disease

Researchers analyzed single-cell transcriptomes from early, middle, and late stages of AD to identify subtle shifts in cellular activity. They found that mitochondria in vulnerable brain areas began to fail early in the disease, even before amyloid plaque buildup. The study also identified a gene called MEG3 involved in regulating mito...

SourceBGI Genomics·JournalProtein & Cell·DateJun 25, 2025

A new timeline for Parkinson's disease

Researchers at La Jolla Institute for Immunology discovered that T cell reactivity is highest during the prodromal period in Parkinson's disease, which can last for decades before noticeable symptoms. This finding may guide the development of early diagnostic tools and provide a new timeline for Parkinson's disease detection.

SourceLa Jolla Institute for Immunology·Journalnpj Parkinson s Disease·TypeExperimental study·DateJun 18, 2025

Mood disorders in late-life may be early warning signs for dementia

Research found that approximately 50% of participants with late-life depression and bipolar disorder showed tau accumulation in their brains, compared to only about 15% of healthy controls. The study suggests that neurodegenerative diseases, including Alzheimer's, can initially manifest as psychiatric symptoms.

SourceThe National Institutes for Quantum Science and Technology·JournalAlzheimer s & Dementia·TypeObservational study·DateJun 9, 2025

New study links longer reproductive years to healthier brain aging in women

A new study suggests that women who spend more time in their reproductive phase may experience slower brain aging. Estradiol, the most potent form of estrogen during this period, may help protect the brain from age-related decline. However, further research is needed to fully understand the relationship between estradiol and brain health.

SourceUniversity of Auckland·JournalGigaScience·TypeData/statistical analysis·DateJun 4, 2025

ATN biomarker dataset now available on the EPND Hub – advancing research into Alzheimer’s disease, Parkinson’s disease, and Dementia with Lewy Bodies

The ATN dataset is a multi-cohort study that includes harmonised clinical and biomarker data from over 350 participants across ten European research cohorts. This dataset provides valuable insights into shared disease mechanisms among Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies.

Candidate drug that boosts protective brain protein in mice has potential to treat Alzheimer’s Disease

Researchers at UCLA Health identified a candidate small molecule, DDL-357, that increases concentrations of secreted clusterin, reducing toxic protein phospho-tau and improving mitochondrial function. The drug also improved memory in treated mice in maze-based cognitive tests.

SourceUniversity of California - Los Angeles Health Sciences·Journalnpj Drug Discovery·TypeRandomized controlled/clinical trial·DateMay 20, 2025